Clinical activity of irofulven in hormone refractory prostate cancer.

被引：0
|
作者：
Cvitkovic, E
Kahatt, C
Senzer, N
Tombal, B
Culine, S
Raymond, E
Alexandre, J
Weems, G
MacDonald, J
机构：
[1] Cvitkovic & Associes Consultants, Le Kremlin Bicetre, France
[2] Mary Crowley Med Res Ctr, US Oncol, Dallas, TX USA
[3] UCLC St Luc, Brussels, Belgium
[4] CRLC, Montpellier, France
[5] Inst Gustave Roussy, Villejuif, France
[6] Hop Cochin, F-75674 Paris, France
[7] MGI Pharma Inc, Bloomington, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4766
引用
收藏
页码：447S / 447S
页数：1
相关论文
共 50 条
  • [1] Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial
    Senzer, N
    Arsenau, J
    Richards, D
    Berman, B
    MacDonald, JR
    Smith, S
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (01): : 36 - 42
  • [2] A phase I study of silibinin in hormone refractory prostate cancer.
    Flaig, T
    Agarwal, R
    Su, LJ
    Harrison, GS
    Gustafson, DL
    Glode, LM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 427S - 427S
  • [3] Clinical activity of transdermal estradiol in patients with hormone and chemotherapy refractory prostate cancer
    Chhabra, S.
    Doyle-Lindrud, S.
    Jeyamohan, C.
    Metzger, D.
    Todd, M. B.
    DiPaola, R. S.
    Goodin, S.
    Stein, M. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Satraplatin: A new treatment option for patients with hormone refractory prostate cancer.
    Nathan, FE
    Sternberg, C
    Sartor, O
    Petrylak, D
    Witjes, F
    Wosikowski, K
    Petrone, ME
    Rozencweig, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 453S - 453S
  • [5] Etoposide and estramustine in previously treated hormone-refractory prostate cancer.
    Pavese, I.
    Di Palma, M.
    Mazzoli, M.
    Burattini, E.
    Satta, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Soy isoflavones and lycopene in the treatment of hormone-sensitive and hormone-refractory prostate cancer.
    Vaishampayan, UV
    Forman, JJ
    Hussain, M
    Cher, M
    Pontes, E
    Fontana, J
    Alluri, KC
    Doerge, D
    Sarkar, F
    Kucuk, O
    JOURNAL OF NUTRITION, 2004, 134 (05): : 1258S - 1258S
  • [7] Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer.
    Breton, X
    Lechevallier, E
    Coulange, C
    PROGRES EN UROLOGIE, 2005, 15 (03): : 398 - 404
  • [8] Intermediate end point for survival for patients with hormone refractory metastatic prostate cancer.
    D'Amico, AV
    Chen, MH
    Cox, MC
    Dahut, W
    Figg, WD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 391S - 391S
  • [9] Therapeutic implications of the revised concept of hormone-refractory metastatic prostate cancer.
    Paule, B
    PROGRES EN UROLOGIE, 2004, 14 (06): : 1119 - 1124
  • [10] Preclinical assessment of PSP-94 for the treatment of hormone refractory prostate cancer.
    Garde, SV
    Fraser, JE
    Chambers, AF
    Ilenchuk, TT
    CLINICAL CANCER RESEARCH, 1999, 5 : 3840S - 3840S
12345